Complete Genomics to Vigorously Defend Against Patent Infringement Suit
News Jun 28, 2012
Complete Genomics, Inc. has announced that it intends to vigorously defend itself against the patent infringement suit recently filed by Illumina, Inc. in the U.S. District Court for the Southern District of California.
The complaint alleges that Complete infringes a single Illumina patent relating to a "Method for Sequencing a Polynucleotide Template." Complete considers the lawsuit to be wholly without merit.
"Despite this move by Illumina, we remain fully committed to the strategy and actions that we recently announced," stated Dr. Clifford A. Reid, Ph.D., Complete's chairman, president and chief executive officer.
Dr. Reid continued, "We will continue to fully service and support our customers while defending against this lawsuit. This is yet another attempt by Illumina to compete in the courtroom instead of the marketplace and reflects the extent to which it sees Complete's more accurate genome sequencing technology as a competitive threat."
In August 2010, Illumina used Complete for infringement of another patent, in a case now pending in the U.S. District Court for the Northern District of California.
Complete considers that suit to also be without merit and recently filed a motion for summary judgment setting forth numerous grounds for the patent in issue being declared invalid.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018